Perflenapent

Drug Profile

Perflenapent

Alternative Names: DDFPe; Dodecafluoropentane; NVX-108; Perfluoropentane; PFP

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NuvOx Pharma
  • Class Diagnostic agents; Fluorocarbons; Radiation-sensitising agents; Radiosensitisers; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma

Most Recent Events

  • 02 Jun 2017 Adverse events data from a phase I/II trial in presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 NuvOx Pharma plans a phase II trial for glioblastoma multiforme in USA
  • 10 Apr 2017 The US FDA approves IND application for perflenapent in Glioblastoma multiforme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top